Osteologie 2008; 17(04): 219-221
DOI: 10.1055/s-0037-1619870
Schmerz bei Osteoporose
Schattauer GmbH

Wirkung von Bisphophonaten auf Osteoporoseschmerzen

Analgetic effect of bisphosphonates in osteoporotic pain
D. Schöffel
1   Westpfalz-Klinikum GmbH, Kusel, Abteilung für Rheumatologie
› Author Affiliations
Further Information

Publication History

Publication Date:
28 December 2017 (online)


Die analgetische Wirkung der Bisphosphonate in der Onkologie wurde vielfach nachgewiesen. Bei Nichttumorschmerzen ist deren schmerzstillende Wirkung weniger gut dokumentiert. Zwar gibt es eine Vielzahl tierexperimenteller Daten zur analgetischen Wirkung von Bisphosphonaten, aber nur in einer einzigen placebokontrollierten Studie konnte eine mäßige analgetische Wirkung von Pamidronat nachgewiesen werden. Auf der anderen Seite können Bisphosphonate bei der Erstgabe von Langzeitpräparaten Schmerzen und grippeähnliche Symptome auslösen; dieser Effekt kann durch eine adäquate Vorbehandlung der Patienten verhindert werden.


The analgesic effect of bisphosphonates in malignant tumours is well known. In non-malignant pain there is a variety of experimental data showing an analgesic effect of bisphosphonates. Clinical data are rare; in a single placebo controlled trial a moderate analgesic effect of pamidronate has been shown. On the other side bisphosphonates can cause pain and flue-like symptoms when administered for the first time; preventive measures for this effect should be taken.

  • Literatur

  • 1 Abdulla AJ. Use of pamidronate for acute pain relief following osteoporotic vertebral fractures. Rheumatology (Oxford) 2000; 39: 567-568.
  • 2 Abildgaard N, Rungby J, Glerup H. et al. Longterm oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998; 61: 128-134.
  • 3 Adami S, Bhalla AK, Dorizzi R. et al. The acute phase response after bisphosphonate administration. Calcified Tissue Int 1987; 41: 326-331.
  • 4 Armingeat T, Brondino R, Pham T. et al. Intravenous Pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporosis Int 2006; 17: 1659-1665.
  • 5 Bianchi M, Franchi S, Ferrario P. et al. Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. Eur J Pain 2008; 12: 284-292.
  • 6 Bock O, Boerst H, Thomasius FE. et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and riesedronate in patients with osteoporosis and ways of their prevention. J Musculoskeletal and neuronal Interactions 2007; 07: 144-148.
  • 7 Clemens MR, Fessele K, Heim ME. Effect of daily dichloromethylene bisphosphonate on skeletal complications. Annals Hematology 1993; 66: 141-146.
  • 8 Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 09: 389-406.
  • 9 Gober HJ, Kistowska M, Angman L. et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-168.
  • 10 Hewitt RE, Lissina A, Green AE. et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by periphereal gd T cells in response to aminobisphosponates is inhibited by statins. Clin Exp Immunol 2005; 139: 101-111.
  • 11 Kawabata A. Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant induced arthritis: involvement of ATP-sensitive K+ channels. Neuropharmacology 2006; 51: 182-190.
  • 12 Nagae M, Hiraga T, Wakabayashi H. et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone 2006; 39: 1107-1115.
  • 13 Papapoulos SE, Hamdy NA, van der Pluijm G. Bisaphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 2000; 88: 3047-3053.
  • 14 Pickering LM, Mansi JL. The role of bisphosphonates in breast cancer managemenet: review article. Curr Med Res Opin 2002; 18: 284-295.
  • 15 Rovetta G, Monteforte P, Balestra V. Intravenous clodronate for acute pain induced by osteoporotic vertebral fractures. Drugs Exp Clin Res 2000; 26: 25-30.
  • 16 Van Beek E, Pieterman E, Cohen L. et al. Nitrogencontaining bisphosphonates inhibit isopentenyl pyrophosphat isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to thei antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999; 255: 491-494.
  • 17 Walker K, Medhurst S, Kidd B. et al. Disease modifying and anti-nociceptive effects of the bisphosphonate zoledronic acid in a model of bone cancer pain. Pain 2002; 100: 219-229.
  • 18 Wysocki DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Int Med 2005; 165: 346-347.